Bookchin R M, Balazs T
Blood. 1986 Apr;67(4):887-92.
Factors contributing to the clinical differences between sickle cell-hemoglobin C disease (SC) and the benign sickle cell trait (AS) include the higher proportion of hemoglobin (Hb) S and the higher cell Hb concentrations in SC compared with AS red cells. Reports differ, however, about whether Hb C copolymerizes more than Hb A with Hb S when measured by minimum gelling concentrations (MGCs) and polymer solubilities of the deoxy-Hb mixtures. We now show that the MGCs and solubilities of equimolar mixtures of Hb S + Hb C vary much more with the ionic strength (mu) of the solution than those of Hb S + Hb A mixtures. At mu less than or equal to 0.20, but not at mu greater than 0.25, Hb S + Hb C solubilities were significantly lower than those of Hb S + Hb A. These differences which may reflect a greater effect of the beta 6Lys+ in Hb C at lower mu, can account for the reported discrepancies. The solubility differences were similar in the presence or absence of asymmetric hybrids, and since the intratetramerically cross-linked hybrids alpha 2 beta s beta A and alpha 2 beta s beta c had similar solubilities, they did not indicate the usual mechanism, involving greater incorporation of alpha 2 beta s beta c into the polymers. The small solubility differences between the two Hb mixtures at physiologic (red cell) concentrations of Hb and 2,3-diphosphoglycerate probably play a minor role in the clinical differences between SC and AS states.
导致镰状细胞 - 血红蛋白C病(SC)与良性镰状细胞性状(AS)临床差异的因素包括,与AS红细胞相比,SC中血红蛋白(Hb)S的比例更高以及细胞内Hb浓度更高。然而,关于通过脱氧 - Hb混合物的最低凝胶浓度(MGCs)和聚合物溶解度测量时,Hb C与Hb S共聚是否比Hb A与Hb S共聚更多,各报告存在差异。我们现在表明,与Hb S + Hb A混合物相比,Hb S + Hb C等摩尔混合物的MGCs和溶解度随溶液离子强度(μ)的变化要大得多。在μ小于或等于0.20时,但在μ大于0.25时则不然,Hb S + Hb C的溶解度显著低于Hb S + Hb A的溶解度。这些差异可能反映了在较低μ时Hb C中β6Lys +的更大作用,这可以解释所报道的差异。在存在或不存在不对称杂合体的情况下,溶解度差异相似,并且由于四聚体内交联的杂合体α2βsβA和α2βsβc具有相似的溶解度,它们并未表明通常的机制,即涉及α2βsβc更多地掺入聚合物中。在生理(红细胞)浓度的Hb和2,3 - 二磷酸甘油酸下,两种Hb混合物之间的小溶解度差异可能在SC和AS状态的临床差异中起次要作用。